Skip to main content

Research Repository

Advanced Search

All Outputs (47)

Phenotypic characterization of breast cancer: the role of CDC42 (2017)
Journal Article
Chrysanthou, E., Gorringe, K. L., Joseph, C., Craze, M. L., Nolan, C. C., Diez-Rodriguez, M., …Mukherjee, A. (2017). Phenotypic characterization of breast cancer: the role of CDC42. Breast Cancer Research and Treatment, 164(2), https://doi.org/10.1007/s10549-017-4267-8

Purpose: The molecular landscape of breast cancer (BC), especially of the Luminal A subtype, remains to be fully delineated. Transcriptomic data shows that Luminal A tumours are enriched for aberrant expression of genes in the cell division control 4... Read More about Phenotypic characterization of breast cancer: the role of CDC42.

Prognostic significance of tumour infiltrating B-Lymphocytes in breast ductal carcinoma in situ (2017)
Journal Article
Miligy, I., Mohan, P., Gaber, A., Aleskandarany, M. A., Nolan, C. C., Diez‐Rodriguez, M., …Rakha, E. A. (2017). Prognostic significance of tumour infiltrating B-Lymphocytes in breast ductal carcinoma in situ. Histopathology, 71(2), 258-268. https://doi.org/10.1111/his.13217

Aims: Tumour?infiltrating lymphocytes (TILs) are an important component of the immune response to cancer and have a prognostic value in breast cancer. Although several studies have investigated the role of T lymphocytes in breast cancer, the role of... Read More about Prognostic significance of tumour infiltrating B-Lymphocytes in breast ductal carcinoma in situ.

Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications (2016)
Journal Article
Agboola, A. O., Ebili, H. O., Iyawe, V. O., Banjo, A. A., Salami, B. A., Rakha, E. A., …Green, A. R. (2017). Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications. Pathology - Research and Practice, 213(1), 27-33. https://doi.org/10.1016/j.prp.2016.10.005

Ku 70/80 is a regulator of the Non-Homologous End Joining (NHEJ) roles in clinicopathological features, and has prognostic significance in breast cancer (BC) in Caucasian populations. However, its significance in the Nigerian BC population, which is... Read More about Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications.

Further evidence to support bimodality of oestrogen receptor expression in breast cancer (2016)
Journal Article
Muftah, A. A., Aleskandarany, M., Sonbul, S. N., Nolan, C. C., Diez Rodriguez, M., Caldas, C., …Rakha, E. A. (2017). Further evidence to support bimodality of oestrogen receptor expression in breast cancer. Histopathology, 70(3), 456-465. https://doi.org/10.1111/his.13089

Aims: Although oestrogen receptor (ER)‐negative breast cancers (BCs) do not respond to hormone therapy, the response of ER‐positive BCs is reported to be variable, which may suggest a dose‐dependent effect. The aim of this study was to assess the pat... Read More about Further evidence to support bimodality of oestrogen receptor expression in breast cancer.

Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein (2016)
Journal Article
Alshareeda, A., Negm, O. H., Aleskandarany, M. A., Green, A. R., Nolan, C., Tighe, P. J., …Rakha, E. (2016). Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein. Breast Cancer Research and Treatment, 159(1), 41-53. https://doi.org/10.1007/s10549-016-3915-8

Impaired DNA damage response (DDR) may play a fundamental role in the pathogenesis of breast cancer (BC). RAD51 is a key player in DNA double-strand break repair. In this study, we aimed to assess the biological and clinical significance of RAD51 exp... Read More about Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours (2016)
Journal Article
Green, A. R., Aleskandarany, M. A., Agarwal, D., Elsheikh, S., Nolan, C. C., Diez-Rodriguez, M., …Rakha, E. A. (2016). MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. British Journal of Cancer, 114(8), 917-928. https://doi.org/10.1038/bjc.2016.46

Background: MYC is amplified in approximately 15% of breast cancers (BCs) and is associated with poor outcome. c-MYC protein is multi-faceted and participates in many aspects of cellular function and is linked with therapeutic response in BCs. We... Read More about MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.

The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts (2016)
Journal Article
Aleskandarany, M. A., Agarwal, D., Negm, O. H., Ball, G., Elmouna, A., Ashankyty, I., …Rakha, E. A. (2016). The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts. Breast Cancer Research and Treatment, 156(1), 9-20. https://doi.org/10.1007/s10549-016-3709-z

Signal transducer and activator of transcription (STAT) transcription factors family are involved in diverse cellular biological functions. Reports regarding the prognostic impact of STAT3 expression in breast cancer (BC) are variable whether being a... Read More about The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts.

Clinical utility of reverse phase protein array for molecular classification of breast cancer (2015)
Journal Article
Negm, O. H., Muftah, A. A., Aleskandarany, M. A., Hamed, M. R., Ahmad, D. A., Nolan, C. C., …Green, A. R. (2016). Clinical utility of reverse phase protein array for molecular classification of breast cancer. Breast Cancer Research and Treatment, 155(1), 25-35. https://doi.org/10.1007/s10549-015-3654-2

Reverse Phase Protein Array (RPPA) represents a sensitive and high-throughput technique allowing simultaneous quantitation of protein expression levels in biological samples. This study aimed to confirm the ability of RPPA to classify archival formal... Read More about Clinical utility of reverse phase protein array for molecular classification of breast cancer.

Construction of tissue microarrays from core needle biopsies: a systematic literature review (2015)
Journal Article
Albanghali, M., Green, A., Rakha, E., Aleskandarany, M., Nolan, C., Ellis, I., & Cheung, K. (2016). Construction of tissue microarrays from core needle biopsies: a systematic literature review. Histopathology, 68(3), 323-332. https://doi.org/10.1111/his.12802

In some clinical circumstances, core needle biopsy (CNB) may be the only source of material from cancer tissue for diagnostic use. The volume of tissue available in a CNB is low, and opportunities for research use can therefore be limited. The tissue... Read More about Construction of tissue microarrays from core needle biopsies: a systematic literature review.

The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer (2015)
Journal Article
Magnani, L., Patten, D. K., Nguyen, V. T. M., Hong, S., Steel, J. H., Patel, N., …Coombes, C. R. (2015). The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer. Oncotarget, 6(26), 21878-21891. https://doi.org/10.18632/oncotarget.4243

Over 30% of ER? breast cancer patients develop relapses and progress to metastatic disease despite treatment with endocrine therapies. The pioneer factor PBX1 translates epigenetic cues and mediates estrogen induced ER? binding. Here we demonstrate t... Read More about The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer.

KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer (2015)
Journal Article
Alshareeda, A., Negm, O., Green, A., Nolan, C., Tighe, P., Albarakati, N., …Rakha, E. (2015). KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer. British Journal of Cancer, 112(12), 1929–1937. https://doi.org/10.1038/bjc.2015.165

Background: It is recognised that modulations of the nuclear import of macromolecules have a role in changing cellular phenotypes and carcinogenesis. We and others have noticed that aberrant subcellular localisation of DNA damage response (DDR) prote... Read More about KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer.

Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification (2015)
Journal Article
Aleskandarany, M. A., Soria, D., Green, A. R., Nolan, C., Diez-Rodriguez, M., Ellis, I. O., & Rakha, E. A. (2015). Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification. Breast Cancer Research and Treatment, 151(2), 325-333. https://doi.org/10.1007/s10549-015-3406-3

Accurate distant metastasis (DM) prediction is critical for risk stratification and effective treatment decisions in breast cancer (BC). Many prognostic markers/models based on tissue marker studies are continually emerging using conventional statist... Read More about Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification.

The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways (2015)
Journal Article
Jerjees, D. A., Negm, O. H., Alabdullah, M. L., Mirza, S., Alkaabi, M., Hameed, M. R., …Rakha, E. A. (2015). The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways. Breast Cancer Research and Treatment, 150(1), 91-103. https://doi.org/10.1007/s10549-015-3308-4

The mammalian target of rapamycin complex 1 (mTORC1) is a downstream of the PI3K/Akt pathway which affects cancer development. mTORC1 has many downstream signalling effectors that can enhance different cellular responses. This study aims to investiga... Read More about The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers (2015)
Journal Article
Aleskandarany, M., Caracappa, D., Nolan, C. C., Macmillan, R. D., Ellis, I. O., Rakha, E. A., & Green, A. R. (2015). DNA damage response markers are differentially expressed in BRCA-mutated breast cancers. Breast Cancer Research and Treatment, 150(1), 81-90. https://doi.org/10.1007/s10549-015-3306-6

Cells have stringent DNA repair pathways that are specific for each different set of DNA lesions which is accomplished through the integration of complex array of proteins. However, BRCA-mutated breast cancer (BC) has defective DNA repair mechanisms.... Read More about DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.

Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response (2015)
Journal Article
Al-kaabi, M., Alshareeda, A., Jerjees, D., Muftah, A., Green, A., Alsubhi, N., …Rakha, E. (2015). Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response. British Journal of Cancer, 112(5), 901-911. https://doi.org/10.1038/bjc.2014.576

Background: Checkpoint kinase1 (CHK1), which is a key component of DNA-damage-activated checkpoint signalling response, may have a role in breast cancer (BC) pathogenesis and influence response to chemotherapy. This study investigated the clinicop... Read More about Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response.

Biological and clinical significance of PARP1 protein expression in breast cancer (2014)
Journal Article
Green, A. R., Caracappa, D., Benhasouna, A. A., Alshareeda, A., Nolan, C. C., Macmillan, R. D., …Rakha, E. A. (2015). Biological and clinical significance of PARP1 protein expression in breast cancer. Breast Cancer Research and Treatment, 149(2), 353-362. https://doi.org/10.1007/s10549-014-3230-1

Poly(ADP-ribose) polymerase-1 (PARP1) is a key facilitator of DNA repair. PARP inhibitors have gained recent attention as promising therapeutic agents for the treatment of solid tumours including breast cancer (BC). However, the biological and clinic... Read More about Biological and clinical significance of PARP1 protein expression in breast cancer.

ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer (2014)
Journal Article
Jerjees, D. A., Alabdullah, M., Alkaabi, M., Abduljabbar, R., Muftah, A., Nolan, C., …Rakha, E. A. (2014). ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer. Breast Cancer Research and Treatment, 147(1), 25-37. https://doi.org/10.1007/s10549-014-3066-8

The extracellular-regulated kinase (ERK) 1/2 is one of the members of the mitogen-activated protein kinases (MAPKs). MAPKs are transduction proteins that play a role in controlling diverse cellular functions including proliferation and survival. In b... Read More about ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer.

Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts. (2014)
Journal Article
Syed, B. M., Green, A. R., Nolan, C. C., Morgan, D. A., Ellis, I. O., & Cheung, K. (2014). Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts. PLoS ONE, 9(7), doi:10.1371/journal.pone.0100573. ISSN 1932-6203

Triple negative (ER, PgR and HER2 negative) breast cancers (TNBCs) are often considered as a poor prognostic phenotype. There is dearth of evidence showing the prevalence and biological behaviour of TNBCs in older women. This study aimed to analyse t... Read More about Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts..

Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study (2014)
Journal Article
Aleskandarany, M. A., Negm, O. H., Green, A. R., Ahmed, M. A. H., Nolan, C. C., Tighe, P. J., …Rakha, E. A. (2014). Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study. Breast Cancer Research and Treatment, 145(2), 339-348. https://doi.org/10.1007/s10549-014-2927-5

Epithelial mesenchymal transition (EMT), as defined by loss of epithelial characteristics and gain of a mesenchymal phenotype, has been reported in vivo although the occurrence of events remains unclear. This study aims at exploration of EMT portrait... Read More about Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study.

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer (2014)
Journal Article
Green, A. R., Barros, F. F., Abdel-Fatah, T. M., Moseley, P., Nolan, C. C., Durham, A. C., …Ellis, I. O. (2014). HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer. Breast Cancer Research and Treatment, 145(1), 33-44. https://doi.org/10.1007/s10549-014-2925-7

Human epidermal growth factor receptor 2 (HER2) plays an important role in breast cancer progression and provides predictive information for response to targeted therapy including trastuzumab although this is limited. Downstream pathways, such as PI3... Read More about HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer.